emilimogene sigulactibac topical (ILP-100 topical) / Ilya Pharma - LARVOL DELTA

Ilya Pharma receives Rare Pediatric Disease Designation from the U.S. FDA for emilimogene sigulactibac for the treatment of skin wounds in SAVI patients (Cision) - "Ilya Pharma (the Company), a clinical stage immunotherapy company today announced that it has received a Rare Pediatric Disease Designation by the U.S FDA....'Pediatric patients living with SAVI face a significant unmet medical need with limited treatment options,'...“Obtaining Rare Pediatric Disease Designation is another acknowledgement of the serious and life-threatening manifestations of this rare disease, and supports our mission to provide emilimogene sigulactibac as a potential new treatment option.'"

FDA event • Interferonopathies • STING-Associated Vasculopathy with Onset in Infancy